| Autoantibodies in ... | Inherited mutations in ... | Molecule | Targeted by ... | % Correct |
|---|---|---|---|---|
| - | X-linked agammaglobulinemia (XLA) | Bruton's tyrosine kinase (BTK) | Ibrutinib, acalabrutinib, zanubrutinib | 100%
|
| - | Liddle's syndrome, pseudohypoaldosteronism type I | Epithelial sodium channel (ENaC) | Amiloride, triamterene | 100%
|
| Immune thrombocytopenia purpura (ITP) | Glanzmann's thrombasthenia | Glycoprotein IIb/IIIa (GPIIb/IIIa) | Abciximab, eptifibatide, tirofiban | 100%
|
| Anti-_______ immune-mediated necrotizing myopathy (IMNM) | Limb-girdle muscular dystrophy (LGMD) | HMG-CoA reductase (HMGCR) | Statins | 100%
|
| Myasthenia gravis (MG) | Congenital myasthenic syndrome (CMS) | Nicotinic acetylcholine receptor (nAChR) | Rocuronium, succinylcholine (suxamethonium) | 100%
|
| Anti-____ encephalitis | GRIN disorders | NMDA-R | Ketamine, memantine | 100%
|
| Acquired Gitelman syndrome | Gitelman syndrome | Sodium-chloride cotransporter (NCC / NCCT) | Hydrochlorothiazide, chlorthalidone, metolazone | 100%
|
| - | Bartter syndrome | Sodium-potassium-chloride cotransporter (NKCC) | Furosemide, bumetanide | 100%
|
| Autoimmune thyroiditis | - | Thyroid peroxidase (TPO) | Methimazole, propylthiouracil (PTU) | 100%
|
| Anti-______ systemic sclerosis (SSc) | - | Topoisomerase I (Scl-70) | Irinotecan, topotecan | 100%
|